Data_Sheet_1_A Comprehensive Investigation to Reveal the Relationship Between Plasmacytoid Dendritic Cells and Breast Cancer by Multiomics Data Analysis.PDF

Plasmacytoid dendritic cells (pDC) are an essential immune microenvironment component. They have been reported for crucial roles in linking the adaptive and immune systems. However, the prognostic role of the pDC in breast cancer (BRCA) was controversial. In this work, we collected large sample cohorts and did a comprehensive investigation to reveal the relationship between pDC and BRCA by multiomics data analysis. Elevated pDC levels were correlated with prolonged survival outcomes in BRCA patients. The distinct mutation landscape and lower burden of somatic copy number alterations (SCNA) and lower intratumoral heterogeneity were observed in the high pDC abundance group. Additionally, a more sensitive immune response and chemotherapies response were observed in the high pDC group, which implicates that patients with high pDC abundance can be benefited from the combination of chemotherapy and immunotherapy. In conclusion, the correlation between pDC abundance and BRCA patients’ overall survival (OS) was found to be positive. We identified the molecular profiles of BRCA patients with pDC abundance. Our findings may be beneficial in aiding in the development of immunotherapy and elucidating on the precision treatment for BRCA.

浆细胞样树突状细胞（plasmacytoid dendritic cells, pDC）是免疫微环境的核心组成成分。既往研究证实，其在衔接适应性免疫系统与固有免疫系统中发挥关键调控作用。然而，浆细胞样树突状细胞在乳腺癌（BRCA）中的预后价值仍存在争议。本研究收集了大样本临床队列，通过多组学数据分析全面探究了pDC丰度与乳腺癌之间的关联。研究结果显示，乳腺癌患者体内pDC水平升高与更长的生存预后显著相关。在pDC丰度较高的患者亚组中，可观察到独特的突变谱、更低的体细胞拷贝数变异（somatic copy number alterations, SCNA）负荷以及更低的肿瘤内异质性。此外，高pDC丰度群体的免疫应答与化疗应答均更为敏感，这提示该类乳腺癌患者可从化疗联合免疫治疗方案中获益。综上，本研究证实pDC丰度与乳腺癌患者的总生存期（overall survival, OS）呈正相关关系。我们鉴定了伴随不同pDC丰度的乳腺癌患者的分子特征谱。本研究结果可为乳腺癌免疫治疗的开发提供理论参考，并有助于阐明乳腺癌的精准治疗策略。